Advanced search
Publication Cover
Journal of Medical Economics Volume 26, 2023 - Issue 1
Submit an article Journal homepage
2,001
Views
1
CrossRef citations to date
0
Altmetric
Neurology

Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

Paulos Gebrehiweta Cytokinetics, Incorporated, South San Francisco, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7692-2189
ORCID Icon,
Lisa Menga Cytokinetics, Incorporated, South San Francisco, CA, USA
,
Stacy A. Rudnickia Cytokinetics, Incorporated, South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-3499-5208
ORCID Icon,
Phil Saroccoa Cytokinetics, Incorporated, South San Francisco, CA, USA
,
Jenny Weia Cytokinetics, Incorporated, South San Francisco, CA, USA
,
Andrew A. Wolffa Cytokinetics, Incorporated, South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-9094-0359
ORCID Icon,
Michael Butznera Cytokinetics, Incorporated, South San Francisco, CA, USAORCID Iconhttps://orcid.org/0000-0002-6015-7910
ORCID Icon,
Adriano Chiòb ‘Rita Levi Montalcini’ Department of Neuroscience, University of Turin, Turin, ItalyORCID Iconhttps://orcid.org/0000-0001-9579-5341
ORCID Icon,
Jinsy A. Andrewsc The Neurological Institute of New York, Columbia University Irving Medical Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-3474-7140
ORCID Icon,
Angela Genged Clinical Research Unit, Montreal Neurological Institute-Hospital, Montreal, QC, CanadaORCID Iconhttps://orcid.org/0000-0001-5587-9946
ORCID Icon,
Dyfrig A. Hughese Centre for Health Economics & Medicines Evaluation, School of Medical and Health Sciences, Bangor University, Bangor, UKORCID Iconhttps://orcid.org/0000-0001-8247-7459
ORCID Icon,
Carlayne E. Jacksonf Department of Neurology, University of Texas Health Science Center at San Antonio, TX, USAORCID Iconhttps://orcid.org/0000-0002-9368-395X
ORCID Icon,
Noah Lechtzing Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0002-9088-8749
ORCID Icon,
Timothy M. Millerh Department of Neurology, Washington University School of Medicine, St. Louis, MO, USAORCID Iconhttps://orcid.org/0000-0002-3424-5511
ORCID Icon &
Jeremy M. Shefneri Barrow Neurological Institute, University of Arizona, Phoenix, AZ, USA;j Department of Neurology, Creighton University, Phoenix, AZ, USAORCID Iconhttps://orcid.org/0000-0001-5067-5602
ORCID Icon show all
Pages 488-493 | Received 17 Feb 2023, Accepted 15 Mar 2023, Published online: 31 Mar 2023

Figures & data

Table 1. Baseline characteristics of patients with ALS in FORTITUDE-ALS.

Table 2. EQ-5D-5L utility scores and QALY for reldesemtiv and placebo in FORTITUDE-ALS.

Table 3. Change from baseline in EQ-5D-5L at all visits.

Table 4. Change from baseline in EQ-5D-5L at all visits for reldesemtiv 150 mg BID and placebo in FORTITUDE-ALS.

Table 5. Change from baseline in EQ-5D-5L at all visits for reldesemtiv 300 mg BID and placebo in FORTITUDE-ALS.

Table 6. Change from baseline in EQ-5D-5L at all visits for reldesemtiv 450 mg BID and placebo in FORTITUDE-ALS.

Table 7. EQ-5D-5L utility scores and QALY for reldesemtiv 150 mg BID and placebo in FORTITUDE-ALS.

Table 8. EQ-5D-5L utility scores and QALY for reldesemtiv 300 mg BID and placebo in FORTITUDE-ALS.

Table 9. EQ-5D-5L utility scores and QALY for reldesemtiv 450 mg BID and placebo in FORTITUDE-ALS.

Data availability statement

The data reported herein are part of a sponsor-led clinical development program that is ongoing, thus complete datasets for the trial will not be made available with this report.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.